Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH.

Nitze LM, Ratziu V, Sanyal AJ, Wong VW, Balendran C, Fleckner J, Skalshøi Kjær M, Krarup N, Anstee QM

Alimentary pharmacology & therapeutics23 Sept 2025Cited by 8 (Europe PMC)

PMID40985232PMCIDPMC12807327DOI10.1111/apt.70376PepBankPUB-40985232

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with MASH, pooled semaglutide arms reduced all non-invasive test scores more than placebo from as early as 28 weeks.
In plain wordsIn people with MASH, semaglutide lowered all liver test scores more than placebo, from as early as 28 weeks.
Peptide
Semaglutide
Outcome
DecreaseNon-invasive test scores versus placebo
Study
n = 268
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 72 weeksAs given in this study (human).
Source sentences
Summary
Semaglutide treatment led to significant reductions versus placebo in all NIT scores from as early as 28 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study explored a panel of NITs for assessing response to semaglutide treatment in patients with MASH randomised in a phase 2b trial (NCT02970942).
Summary · context
The present study was performed using the completer population (268 patients), defined as all patients who were randomised, remained on treatment throughout the trial, and had liver biopsy and NIT results at baseline and week 72.
Report a problemFND-4098523201
02HumanRandomized controlled trialEfficacy outcome
In patients with MASH, more patients on semaglutide than on placebo had MASH improvement when assessed by a 20% NIT response.
In plain wordsIn people with MASH, more people on semaglutide than on placebo showed liver improvement by the test-based response measure.
Peptide
Semaglutide
Outcome
IncreaseMASH improvement by 20% NIT response
Study
n = 268
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 72 weeksAs given in this study (human).
Source sentences
Summary
More patients had MASH improvement and fewer had fibrosis progression versus placebo when assessed by a 20% NIT response (0.5 U for ELF)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study explored a panel of NITs for assessing response to semaglutide treatment in patients with MASH randomised in a phase 2b trial (NCT02970942).
Summary · context
The present study was performed using the completer population (268 patients), defined as all patients who were randomised, remained on treatment throughout the trial, and had liver biopsy and NIT results at baseline and week 72.
Report a problemFND-4098523202
03HumanRandomized controlled trialEfficacy outcome
In patients with MASH, fewer patients on semaglutide than on placebo had fibrosis progression when assessed by a 20% NIT response.
In plain wordsIn people with MASH, fewer people on semaglutide than on placebo had liver scarring get worse by the test-based measure.
Peptide
Semaglutide
Outcome
DecreaseFibrosis progression by 20% NIT response
Study
n = 268
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 72 weeksAs given in this study (human).
Source sentences
Summary
fewer had fibrosis progression versus placebo when assessed by a 20% NIT response (0.5 U for ELF)
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study explored a panel of NITs for assessing response to semaglutide treatment in patients with MASH randomised in a phase 2b trial (NCT02970942).
Summary · context
The present study was performed using the completer population (268 patients), defined as all patients who were randomised, remained on treatment throughout the trial, and had liver biopsy and NIT results at baseline and week 72.
Report a problemFND-4098523203
04HumanRandomized controlled trialEfficacy outcome
In patients with baseline LSM above 8 kPa and ELF above 9.8 U, a larger proportion on semaglutide than on placebo reached LSM below 8 kPa and ELF below 9.8 kPa.
In plain wordsIn people with high liver stiffness and ELF scores at start, more on semaglutide than placebo reached lower scores.
Peptide
Semaglutide
Outcome
IncreaseProportion reaching LSM below 8 kPa and ELF below 9.8 kPa
Study
n: not reported in source
Comparator
Placebo
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 72 weeksAs given in this study (human).
Source sentences
Summary
among patients with baseline LSM > 8 kPa and ELF > 9.8 U, a larger proportion achieved LSM < 8 kPa and ELF < 9.8 kPa with semaglutide versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective study explored a panel of NITs for assessing response to semaglutide treatment in patients with MASH randomised in a phase 2b trial (NCT02970942).
Summary · context
The present study was performed using the completer population (268 patients), defined as all patients who were randomised, remained on treatment throughout the trial, and had liver biopsy and NIT results at baseline and week 72.
Report a problemFND-4098523204

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT02970942

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Novo Nordisk A/Sn = 32030 Nov 2016 to 19 Mar 2020

Hepatobiliary Disorders · Non-alcoholic Steatohepatitis

Trial page ClinicalTrials.govUpdated 16 Nov 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.